Showing 577–592 of 1155 results
The Hepatitis B Virus – Qualitative (PCR) test is a highly sensitive molecular diagnostic tool designed to detect the presence of Hepatitis B viral DNA in a patient’s blood. Utilizing advanced Polymerase Chain Reaction (PCR) technology, it offers early and accurate detection of active HBV infection, even at low viral loads.
Sample Type : 4 mL EDTA plasma or Serum
Methodology : Real-time PCR
TAT : 2 Days
Sample Type : Whole Blood + Serum
Methodology : PCR + reverse hybridisation
TAT : 10 Days
Sample Type : EDTA Plasma +Serum
Methodology : Real-time PCR
TAT : 2 Days
Sample Type : 4 mL EDTA plasma or Serum
Methodology : Real-time PCR
TAT : 2 Days
Sample Type : Serum
Methodology : Chemiluminescence
TAT : 1 Day
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
The Hepatitis E Virus (HEV) Antibody, Total test detects both IgG and IgM antibodies to HEV, enabling identification of both recent and past infections. It offers comprehensive screening for HEV exposure, making it valuable for diagnosing acute hepatitis E and assessing immunity.
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
Sample Type : Serum
Methodology : Chemiluminescence
TAT : 1 Day
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment.
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
The Hereditary Hemochromatosis genetic test detects mutations linked to excessive iron absorption. Using real-time PCR, it identifies genetic risk for iron overload. Results in 15 days.
Sample Type : Whole Blood
Methodology : Real-time PCR
TAT : 15 Days
